CTVA Corteva, Inc. Insider Trading

EVP Robert D. King sells 37,280 CTVA shares at $74.20 for $2.8M, reducing holdings 43.1% to 49.3K shares

King sold 37,280 shares (43.1% of his pre-transaction holdings) on 2025-08-29 at $74.20, with the stock now trading at $73.92, close to the transaction price. His prior buy at CTVA on 2023-11-14 showed a 90-day return of +17.7%, consistent with his cross-ticker track record of 100.00% 90d win rate across 1 prior buy. The current sale occurs when the stock is -4.2% from its 52-week high and up +3.9% over the past 30 days. With CTVA trading at a P/E of 35.88 and annual revenue declining -1.8% year-over-year, this substantial reduction in his equity stake warrants investor attention to whether corporate fundamentals are supporting current valuations.

FUERER CORNEL B sold 55,242 CTVA shares at $68.06 on 2025-05-13, reducing holdings by 35.2%; his prior CTVA sells have been well-timed at 90 days.

Cornel Fuerer sold 55,242 shares of Corteva at $68.06, cutting his holdings from 156,883 to 101,641 shares (35.2% reduction). The transaction occurs near the 52-week high of $68.29, and notably, his prior open-market sales at CTVA (on 2024-11-26 and 2024-05-14) both yielded negative 90-day returns of -1.2% and -10.8%, respectively, establishing a pattern of well-timed exits over a 12-month period. His cross-ticker track record reinforces this pattern: 2 prior sells with a 100% 90-day well-timed rate and an average 90-day return of -6.0%, indicating a history of selling ahead of declines. The current sale, executed at a price 0.0% from the 52-week high, aligns with his demonstrated pattern of discretionary timing around price peaks. Investors should monitor whether this transaction signals similar insight into near-term weakness, particularly given the company's flat annual revenue growth of -1.8% and elevated P/E of 40.89.

TITUS BRIAN sold 26,560 shares of CTVA at $63.74 on 2025-02-20, reducing holdings 70.1%; stock at -5.4% from 52-week high amid negative earnings.

TITUS BRIAN executed a substantial reduction in his CTVA position, selling 26,560 shares (representing a net change of -70.1% of pre-transaction holdings) at $63.74. The timing coincides with the company's recent operating pressure: latest quarterly revenue is $2,326,000,000 with a net loss of $524,000,000, and full-year revenue declined -1.8% year-over-year. The stock currently trades at $62.61, near the lower end of its 52-week range and -5.4% from its 52-week high. With a 49.69 P/E ratio on negative earnings, the company faces valuation and fundamental headwinds. This large proportional reduction by an insider warrants examination of whether it reflects a reassessment of Corteva's near-term prospects or merely a liquidity event.

CEO Charles V. Magro sold 46,905 shares of CTVA at $63.82 for $2,993,477.10; retains 231,895 shares post-transaction.

CEO Charles V. Magro executed a sale of 46,905 shares at $63.82, reducing his holdings by 16.8% from 278,800 to 231,895 shares. The stock is trading near its 52-week high at $63.83 (within $0.01 of transaction price), having gained 4.2% over 90 days, though the company reports a net loss of $524,000,000 in the latest quarter and negative annual revenue growth of -1.8%. The sale occurs at a price level consistent with recent upward momentum, while the company's fundamentals show continued operational challenges with a negative net income and declining year-over-year revenue, creating a disconnect between price strength and financial performance.

SVP Fuerer sells 37,672 CTVA shares at $63.40; prior 2024 sale well-timed as stock fell -10.8% thereafter

Cornel B. Fuerer, SVP, General Counsel and Secretary, sold 37,672 shares (127.0K held post-transaction) at $63.40 on 2024-11-26 for $2,388,367.13. This represents a -22.9% reduction in his CTVA position. His track record at this ticker shows strong timing: a May 2024 sale preceded a -10.8% 90-day decline, and a November 2023 buy preceded a +23.5% 90-day rise. The current stock price of $62.50 is -2.5% from the 52-week high of $64.13, while the company reports a net income loss of $-524,000,000.00 against $2,326,000,000.00 in quarterly revenue, with a notably elevated P/E of 61.88. The sequence of his prior two trades being well-timed at the 90-day mark may merit investor attention as a potential signal, though the company's profitability headwinds appear concurrent with the decision.